Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune,neurodegenerative, and ophthalmic disorders. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain-baré syndrome. The company was incorporated in 2011 and is headquartered in Brisbane, California.
